Innovations, challenges and future prospects of oncoproteomics

Molecular Oncology

Volumn 2, Issue 2, 2008, Pages 153-160

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Cancer biomarkers; Nanobiotechnology; Nanooncology; Oncoproteomics; Personalized medicine; Proteomics

Indexed keywords

ANTHRACYCLINE; ANTIBODY; APTAMER; AUTOANTIBODY; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; GLYCOPROTEIN P; HEAT SHOCK PROTEIN; METHOTREXATE; MITOCHONDRIAL DNA; TRASTUZUMAB; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER STAGING; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; LEUKEMIA CELL; LUNG CANCER; MITOCHONDRION; MOLECULAR PROBE; NANOTECHNOLOGY; NEOPLASM; OCCULT BLOOD TEST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEOMICS; REVIEW; TISSUE MICROARRAY;

HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NANOTECHNOLOGY; NEOPLASM PROTEINS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 46849107938     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.05.003     Document Type: Review

References (35)

1. Carney W.P., Leitzel K., Ali S., Neumann R., and Lipton A. HER-2/neu diagnostics in breast cancer. Breast Cancer Res. 9 (2007) 207
2. Cho W.C., and Cheng C.H. Oncoproteomics: current trends and future perspectives. Expert Rev. Proteomics 4 (2007) 401-410
3. Conrad D.H., Goyette J., and Thomas P.S. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J. Gen. Intern. Med. 23 Suppl. 1 (2008) 78-84
4. D'Amico T.A. Molecular biologic staging of lung cancer. Ann. Thorac. Surg. 85 (2008) S737-S742
5. Drev P., Grazio S.F., and Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 16 (2008) 179-184
6. Ebert M.P., Korc M., Malfertheiner P., and Rocken C. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome. Res. 5 (2006) 19-25
7. Engwegen J.Y., Helgason H.H., Cats A., Harris N., Bonfrer J.M., Schellens J.H., and Beijnen J.H. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 12 (2006) 1536-1544
8. Espina V., Wulfkuhle J., Calvert V.S., Liotta L.A., and Petricoin III E.F. Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol. Biol. 441 (2008) 113-128
9. Gjertsen B.T., and Sjoholt G. Proteomic strategies of therapeutic individualization and target discovery in acute leukemia. In: Daoud S.S. (Ed). Cancer Proteomics (2008), Humana Press, Totowa, New Jersey 161-187
10. Habermann J.K., Bader F.G., Franke C., Zimmermann K., Gemoll T., Fritzsche B., Ried T., Auer G., Bruch H.P., and Roblick U.J. From the genome to the proteome-biomarkers in colorectal cancer. Langenbecks Arch. Surg. 393 (2008) 93-104
11. Hardouin J., Lasserre J.P., Sylvius L., Joubert-Caron R., and Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann. N Y Acad. Sci. USA 1107 (2007) 223-230
12. Helleman J., van der Vlies D., Jansen M.P., Luider T.M., van der Burg M.E., Stoter G., and Berns E.M. Serum proteomic patterns for ovarian cancer monitoring. Int. J. Gynecol. Cancer (2007) 10.1111/j.1525-1438.2007.01139.x
13. Hu S., Yen Y., Ann D., and Wong D.T. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery. Drug Discov. Today 12 (2007) 911-916
14. Hwang S.I., Thumar J., Lundgren D.H., Rezaul K., Mayya V., Wu L., Eng J., Wright M.E., and Han D.K. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene 26 (2007) 65-76
15. Jain K.K. Recent advances in oncoproteomics. Curr. Opin. Mol. Ther. 4 (2002) 203-209
16. Jain K.K. Proteomics-based anticancer drug discovery. In: LaRochelle W.J. (Ed). The Oncogenomics Handbook (2005), The Humana Press, Totowa, New Jersey 123-134
17. Jain K.K. Recent advances in clinical oncoproteomics. J. BUON 12 Suppl. 1 (2007) S31-S38
18. Jain K.K. Cancer biomarkers: current issues and future directions. Curr. Opin. Mol. Ther. 9 (2007) 563-571
19. Jain K.K. Proteomics: Technologies, Markets and Companies (2008), Jain PharmaBiotech Publications, Basel, Switzerland pp. 1-570
20. Jain K.K. Recent advances in nanooncology. Technol. Cancer Res. Treat. 7 (2008) 1-13
21. Jain K.K. Oncoproteomics for personalized management of cancer. In: Daoud S.S. (Ed). Cancer Proteomics (2008), Humana Press, Totowa, New Jersey 81-99
22. Johnson C.J., Zhukovsky N., Cass A.E., and Nagy J.M. Proteomics, nanotechnology and molecular diagnostics. Proteomics 8 (2008) 715-730
23. Kim H.K., Park W.S., Kang S.H., Warda M., Kim N., Ko J.H., Ael-B P., and Han J. Mitochondrial alterations in human gastric carcinoma cell line. Am. J. Physiol. Cell Physiol. 293 (2007) C761-C771
24. Kopf E., and Zharhary D. Antibody arrays - an emerging tool in cancer proteomics. Int. J. Biochem. Cell Biol. 39 (2007) 1305-1317
25. Lin J.F., Xu J., Tian H.Y., Ga X., Chen Q.X., Gu Q., Xu G.J., Song J.D., and Zhao F.K. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int. J. Cancer 121 (2007) 2596-2605
26. Liu C., Shea N., Rucker S., Harvey L., Russo P., Saul R., Lopez M.F., Mikulskis A., Kuzdzal S., and Golenko E. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 7 (2007) 4045-4052
27. Lopez-Pedrera C., Villalba J.M., Siendones E., Siendones E., Barbarroja N., Gomez-Diaz C., Rodriguez-Ariza A., Buendia P., Torres A., and Velasco F. Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics 6 Suppl. 1 (2006) S293-S299
28. Nettikadan S., Radke K., Johnson J., Xu J., Lynch M., Mosher C., and Henderson E. Detection and quantification of protein biomarkers from fewer than ten cells. Mol. Cell. Proteomics 5 (2006) 895-901
29. Patz Jr. E.F., Campa M.J., Gottlin E.B., Kusmartseva I., and Guan X.R. Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J. Clin. Oncol. 25 (2007) 5578-5583
30. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D., Bramwell V.H., Levine M.N., and National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354 (2006) 2103-2111
31. Shangguan D., Cao Z., Meng L., Mallikaratchy P., Sefah K., Wang H., Li Y., and Tan W. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. (2008) 10.1021/pr700894d
32. Schippinger W., Dandachi N., Regitnig P., Hofmann G., Balic M., Neumann R., Samonigg H., and Bauernhofer T. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. Am. J. Clin. Pathol. 128 (2007) 630-637
33. Voduc D., Kenney C., and Nielsen T.O. Tissue microarrays in clinical oncology. Semin. Radiat. Oncol. 18 (2008) 89-97
34. Zhang J.T., and Liu Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer. Treat. Rev. 33 (2007) 741-756
35. Zhao L., Liu L., Wang S., Zhang Y.F., Yu L., and Ding Y.Q. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J. Cancer Res. Clin. Oncol. 133 (2007) 771-782